Antibody Drug Conjugates Market Scope And Analysis

Antibody Drug Conjugates Market Report Scope

Industry Developments and Future Opportunities – Antibody Drug Conjugates Market:

Various initiatives taken by leading players operating in the antibody drug conjugates market are listed below:

1. In June 2023, Innovent Biologics, Inc. and RemeGen Co., Ltd. entered into a clinical trial collaboration and supply agreement for the combination therapies of TYVYT (sintilimab injection) with RC88 [a novel mesothelin (MSLN)-targeting ADC] or RC108 [a novel c-Met-targeting ADC] as potential treatment options for advanced solid tumors in China. Under the agreement, Innovent would provide clinical drug supplies of TYVYT (sintilimab injection) during the clinical trial collaboration. RemeGen would conduct Phase 1/2a clinical trials to study the safety and antitumor activity of the combination therapy of TYVYT (sintilimab injection) with RC88 or RC108 in Chinese patients with advanced solid tumors.
2. In July 2022, AstraZeneca signed a new global development and commercialization agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for DS-1062, Daiichi Sankyo’s proprietary ADC directed toward trophoblast cell-surface antigen 2 (TROP2), a potential new medicine for the treatment of multiple tumor types. DS-1062 is currently in the development phase for its activity against multiple tumors that commonly express TROP2, a cell-surface glycoprotein. TROP2 is overexpressed in almost all non-small cell lung cancers1 and breast cancers—2,3 tumor types, which have been a strategic focus for AstraZeneca for a long. This collaboration indicates AstraZeneca’s strategy to invest in ADC through the successful existing collaboration with Daiichi Sankyo.
3. In January 2022, Gilead Sciences, Inc. entered into two clinical trial collaborations and supply agreements with Merck (MSD outside of Canada and the US) to evaluate the combination of Gilead’s Trodelvy (sacituzumab govitecan-hziy) ADC targeting TROP-2 and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab). As part of this collaboration, Merck is expected to sponsor a global Phase 3 clinical trial of Trodelvy combined with KEYTRUDA as a first-line treatment for patients with metastatic NSCLC.

Competitive Landscape and Key Companies - Antibody Drug Conjugates Market:

ADC Therapeutics SA; Pfizer Inc; F. Hoffmann-La Roche Ltd; ImmunoGen, Inc; GSK Plc; Gilead Sciences Inc; AstraZeneca Plc; Astellas Pharma Inc; RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd. are the prominent antibody drug conjugates market companies. These companies focus on new technologies, existing product advancements, and geographic expansions to meet the growing consumer demand worldwide.